Last Updated on December 30, 2020 by The Health Master
Lupin Limited, global pharmaceutical company, announced the launch of mycophenolate mofetil tablets USP, 500 mg, after Lupin’s alliance partner Concord Biotech Limited (Concord) received an approval for its ANDA from the United States Food and Drug Administration (USFDA)
Mycophenolate mofetil tablets USP, 500 mg, are the generic equivalent of CellCept tablets of Roche Palo Alto LLC, indicated for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplants, and should be used in combination with other immunosuppressants.
Mycophenolate mofetil tablets USP had an annual sales of approximately US$ 87 million in the US, according to IQVIA MAT October 2020.
The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram..
Follow and connect with us on Facebook and Linkedin
Go to main website, click here
